India Vaccines Market Overview, 2028

India Vaccines Market Overview, 2028

When it comes to vaccines, India has worked diligently to make a name for it. It is the world's largest supplier of vaccines, producing sufficient percentage of global demand. Since 2012 India's pharmaceutical industry market value has been growing significantly. The vaccine storage temperature and cold chain logistics play a large role in how India is able to safely deliver life-saving vaccines all across the globe. Vaccination in India is largely focused on the pediatric population, with adult immunization mostly non-existent. India's vaccine landscape is characterized by a network of renowned organizations that have not only contributed significantly to the nation's healthcare but have also played a crucial role in supplying vaccines globally. The Serum Institute of India, based in Pune, stands as the world's largest vaccine manufacturer, producing a wide range of vaccines that are distributed worldwide, including to many developing nations through initiatives like Gavi, the Vaccine Alliance. Bharat Biotech, another leading Indian firm, has gained international recognition for its development of the COVAXIN COVID-19 vaccine, which has been used both domestically and in various countries. These organizations, along with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), are at the forefront of research and development, ensuring a continuous supply of vaccines to meet the ever-growing global demand. With their commitment to innovation and production capacity, these Indian vaccine associations have made substantial contributions to public health and have become pivotal players in the worldwide fight against infectious diseases.

According to the research report, “India Vaccine Market Overview, 2028” published by Bonafide Research, the market is anticipated to grow with more than 10.00% CAGR from 2023 to 2028. During the Coronavirus outbreak, India gained the status of fastest vaccinating country in the world in administering more than two billion Covid-vaccination doses through the indigenously produced vaccines and strengthened the global fight against the Coronavirus by supplying vaccines to more than 100 countries. In recent years, India has witnessed a significant increase in vaccine utilization, marking a crucial milestone in the nation's healthcare journey. This surge can be attributed to a combination of factors that have worked together to expand vaccine coverage and accessibility for its vast population. One of the key drivers of this upward trajectory in vaccine utilization is the government's robust immunization program. India has a well-established Universal Immunization Program (UIP) that aims to provide essential vaccines free of cost to all eligible beneficiaries. Over the years, this program has been expanded to include a growing number of vaccines, covering a wider spectrum of preventable diseases.

This expansion not only enhances the overall health and well-being of the population but also fosters a culture of immunization awareness. Additionally, India has been actively engaged in the global vaccine supply chain. As mentioned earlier, the Serum Institute of India, with its vast production capacity, has played a pivotal role in meeting the global demand for vaccines. This includes vaccines not only for domestic use but also for international distribution, often through initiatives like COVAX. This increased involvement on the global stage has not only bolstered India's reputation as a reliable supplier but has also contributed to the nation's vaccine utilization as it reinforces the importance of immunization. Furthermore, advancements in healthcare infrastructure and technology have played a significant role. India has made substantial progress in expanding its healthcare facilities, particularly in rural areas, making vaccines more accessible to a broader segment of the population. The use of digital platforms for vaccine registration and tracking has also streamlined the process, ensuring that vaccines reach the right individuals at the right time. Public awareness campaigns and community engagement have also been instrumental in increasing vaccine utilization. Efforts to educate the public about the importance of immunization and dispel myths and misconceptions have led to greater acceptance and demand for vaccines.

Different vaccine technologies are employed depending on the pathogen (bacteria or virus) that is being targeted. Conjugate vaccines, Inactivated & Subunit vaccines, Live Attenuated vaccines, Recombinant vaccines, and Toxoid vaccinations are all included in this technology. Due to the efficiency and safety profile of conjugated vaccinations, their use in babies has increased dramatically. Conjugated vaccinations offer a dependable way to protect infants from illnesses including Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, Neisseria meningitidis, and others as they are especially susceptible to infections. By drastically lowering the prevalence of these diseases, these immunizations have transformed pediatric healthcare, sparing countless hospital stays and deaths. The high demand for conjugated vaccines in the infant market can be attributed to the increased awareness among parents and healthcare providers about the importance of early immunization, advancements in vaccine technology, and robust vaccination programs implemented by governments and healthcare organizations. Along with this, the inactivated vaccines and subunit vaccines, when the vaccine is introduced to a human through a shot, for example, the inactivated pathogen is strong enough to create an immune response, however, is incapable of causing disease. Multiple doses are often needed in order to build up immunity and offer full protection. The benefit of using this type of vaccine includes Inactivated vaccines can be mass-produced and are relatively inexpensive to make.

Based on the Route of Administration of vaccine, the market is segmented into Intramuscular and Subcutaneous Administration, Oral Administration, and Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.). Intramuscular and Subcutaneous Administration dominates the market, following it the Oral administration of vaccines. The oral route of vaccine delivery gained notable recognition. This mode of administration has garnered attention due to its advantages in terms of accessibility and ease of use. Oral vaccines offer a more patient-friendly approach, particularly for those who may have reservations about needles or for mass vaccination campaigns where a quick, efficient method is required. The market for vaccines is divided into two groups, pediatric vaccines and adult vaccines, according to the end-user of vaccines. The body uses immunity as a means of disease defense. Babies have a higher risk of contracting an infection and developing a serious illness because their immune systems have not fully matured by the time they are born. The use of childhood immunizations is substantially higher than that of adult vaccines. As part of standard immunization schedules, children often receive an extensive series of vaccinations from infancy through puberty. These schedules are carefully created to guard kids against a variety of diseases, such as measles, mumps, rubella, polio, and more. Because of the consistency of the pediatric vaccination schedules, there is a recurrently high demand for these vaccinations. Parental responsibility and understanding are crucial factors in the usage of pediatric vaccines.

Considered in this report:
• Geography: India
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• India Vaccine Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology:
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines

By Route of Administration:
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.)

By End-User:
• Paediatric Vaccines
• Adult Vaccines

By End-User:
• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.)

By Type:
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Institutional Sales
• Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.)

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.